In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Big Pharma's Response to R&D Woes: More Early-Stage Compound Deals

Executive Summary

The earnest tone of the discussions at this year's Pharmaceutical Strategic Alliances Conference reflected an increasingly common assumption among industry executives and insiders: the drug industry's growth problem isn't a merely cyclical issue. Declining productivity, a problem evident in biotech companies as well as Big Pharma, is to blame. Industry executives provided mixed opinions on how to best tackle this challenge, but both Pfizer and Bristol-Myers Squibb suggested a trend towards early-stage compound licensing.
Advertisement

Related Content

Why Deal Accounting Matters
Why Deal Accounting Matters
Testing Drugs Against New Targets: Like Playing Blind Man's Bluff?
Roche Bucks the Trend, with Early-Stage Deals
Testing Drugs Against New Targets: Like Playing Blind Man's Bluff?
Roche Bucks the Trend, with Early-Stage Deals
Why Pharma Needs to Do Early-Stage Deals
Why Pharma Needs to Do Early-Stage Deals

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001780

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel